BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol 2020;10:601710. [PMID: 33330100 DOI: 10.3389/fonc.2020.601710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Shirai D, Shinkawa H, Takemura S, Tanaka S, Amano R, Kimura K, Kinoshita M, Kawada N, Kubo S. Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. Ann Med Surg (Lond) 2021;68:102644. [PMID: 34386231 DOI: 10.1016/j.amsu.2021.102644] [Reference Citation Analysis]
2 Neamatallah M, Serria MS, El‐bendary M, El‐gilany A, Alhawarey A, Abed S, Setate YA, Ammar OA. Association of Vitamin D Gene Polymorphisms With HCV Infection Outcome. Br J Biomed Sci 2022;79:10237. [DOI: 10.3389/bjbs.2021.10237] [Reference Citation Analysis]
3 He Z, Guo T, Cui Z, Xu J, Wu Z, Yang X, Hu H, Mei H, Zhou J, Zhang Y, Wang K. New understanding of Angelica sinensis polysaccharide improving fatty liver: The dual inhibition of lipid synthesis and CD36-mediated lipid uptake and the regulation of alcohol metabolism. Int J Biol Macromol 2022:S0141-8130(22)00618-3. [PMID: 35358574 DOI: 10.1016/j.ijbiomac.2022.03.148] [Reference Citation Analysis]
4 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
5 Zhang W, Zhang H, Zhong Y, Zhang K, Kong H, Yu L, Chen Y, Bai Y, Zhu Z, Yang Y, Gao X. Novel and Specific MRI Features Indicate the Clinical Features of Patients With Rare Hepatic Tumor Epithelioid Hemangioendothelioma. Front Oncol 2022;12:729177. [PMID: 35155220 DOI: 10.3389/fonc.2022.729177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep 2022;12:1517. [PMID: 35087153 DOI: 10.1038/s41598-022-05444-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Xu L, Yang C, Wang J, Li Z, Huang R, Ma H, Ma J, Wang Q, Xiong X. Persistent mTORC1 activation via Depdc5 deletion results in spontaneous hepatocellular carcinoma but does not exacerbate carcinogen- and high-fat diet-induced hepatic carcinogenesis in mice. Biochem Biophys Res Commun 2021;578:142-9. [PMID: 34562654 DOI: 10.1016/j.bbrc.2021.09.036] [Reference Citation Analysis]
8 Radjenović B, Sabo M, Šoltes L, Prnova M, Čičak P, Radmilović-Radjenović M. On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5784. [PMID: 34830937 DOI: 10.3390/cancers13225784] [Reference Citation Analysis]
9 Jang E, Lee JH. Promising Anticancer Activities of Alismatis rhizome and Its Triterpenes via p38 and PI3K/Akt/mTOR Signaling Pathways. Nutrients 2021;13:2455. [PMID: 34371964 DOI: 10.3390/nu13072455] [Reference Citation Analysis]
10 Huang LH, Hsieh TM, Huang CY, Liu YW, Wu SC, Chien PC, Hsieh CH. Disparity of Hepatocellular Carcinoma in Tumor Microenvironment-Related Genes and Infiltrating Immune Cells between Asian and Non-Asian Populations. Genes (Basel) 2021;12:1274. [PMID: 34440448 DOI: 10.3390/genes12081274] [Reference Citation Analysis]
11 Repáraz D, Aparicio B, Llopiz D, Hervás-Stubbs S, Sarobe P. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens? Int J Mol Sci 2022;23:2022. [PMID: 35216137 DOI: 10.3390/ijms23042022] [Reference Citation Analysis]
12 Yang S, Zhang H, Yang H, Zhang J, Wang J, Luo T, Jiang Y, Hua H. SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion. Exp Hematol Oncol 2021;10:17. [PMID: 33622411 DOI: 10.1186/s40164-021-00212-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhu R, Tu Y, Chang J, Xu H, Li JC, Liu W, Do AD, Zhang Y, Wang J, Li B. The Orphan Nuclear Receptor Gene NR0B2 Is a Favorite Prognosis Factor Modulated by Multiple Cellular Signal Pathways in Human Liver Cancers. Front Oncol 2021;11:691199. [PMID: 34055653 DOI: 10.3389/fonc.2021.691199] [Reference Citation Analysis]
14 Liu W, Deng Y, Li Z, Chen Y, Zhu X, Tan X, Cao G. Cancer Evo-Dev: A Theory of Inflammation-Induced Oncogenesis. Front Immunol 2021;12:768098. [PMID: 34880864 DOI: 10.3389/fimmu.2021.768098] [Reference Citation Analysis]
15 Lu Q, Guo Q, Xin M, Lim C, Gamero AM, Gerhard GS, Yang L. LncRNA TP53TG1 Promotes the Growth and Migration of Hepatocellular Carcinoma Cells via Activation of ERK Signaling. Noncoding RNA 2021;7:52. [PMID: 34564314 DOI: 10.3390/ncrna7030052] [Reference Citation Analysis]
16 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
17 Sharma N, Biswas S, Al-Dayan N, Alhegaili AS, Sarwat M. Antioxidant Role of Kaempferol in Prevention of Hepatocellular Carcinoma. Antioxidants (Basel) 2021;10:1419. [PMID: 34573051 DOI: 10.3390/antiox10091419] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Reference Citation Analysis]
19 Xiong Y, Huang J. Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment. Chin Med 2021;16:80. [PMID: 34407830 DOI: 10.1186/s13020-021-00489-0] [Reference Citation Analysis]
20 Yuan M, Shong K, Li X, Ashraf S, Shi M, Kim W, Nielsen J, Turkez H, Shoaie S, Uhlen M, Zhang C, Mardinoglu A. A Gene Co-Expression Network-Based Drug Repositioning Approach Identifies Candidates for Treatment of Hepatocellular Carcinoma. Cancers 2022;14:1573. [DOI: 10.3390/cancers14061573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Yoon YI, Song GW, Lee S, Moon D, Hwang S, Kang WH, Cho HD, Ha SM, Kim MJ, Kim SH, Na BG, Yang G, Min Kim S, Hyun Shim J, Park JI. Salvage living donor liver transplantation versus repeat liver resection for patients with recurrent hepatocellular carcinoma and Child-Pugh class A liver cirrhosis: A propensity score-matched comparison. Am J Transplant 2021. [PMID: 34383368 DOI: 10.1111/ajt.16790] [Reference Citation Analysis]